Edward F. Schnipper MD

Who is Edward F. Schnipper MD?

Edward Schnipper joined Cellgate in 2001 and has more than 18 years of

management experience in the clinical development of medicines for the

pharmaceutical and biotechnology industries. Dr. Schnipper has been

responsible for numerous clinical trial programs that served to support

successful New Drug Application (NDA) strategies and competitive market

positions for new therapeutic products.

Dr. Schnipper was most recently Vice

President of Clinical Development at ALZA Corporation, a specialty

pharmaceutical company. In this role, he was responsible for overseeing

all aspects of the clinical strategy for new pharmaceutical products,

as well as the Phase IV strategies for products both in the company's

pipeline and in its pharmaceutical product portfolio. While at ALZA, he

provided input on research and development efforts and marketing

programs, acted as a spokesperson on company affairs to diverse

external audiences, and provided guidance to scientific and medical

advisory boards for the company. Before joining ALZA, Dr. Schnipper

served as Senior Vice President and Medical Director at SEQUUS

Pharmaceuticals, where he was responsible for clinical and regulatory

functions as a member of the Executive Committee. Between 1983 and

1996, he held various positions at Hoffmann-La Roche, culminating in

his appointment as Vice President of Clinical Operations, Virology.

Dr. Schnipper earned his BA degree from

Hobart College in Geneva, New York and his MD from the Georgetown

University School of Medicine in Washington DC. He trained in medicine

at the Long Island Jewish-Hillside Medical Center and completed

fellowships in hematology at New York University and in medical

oncology at Memorial Sloan-Kettering Cancer Center in New York. He is

a member of the American Society of Clinical Oncology and the American

Academy of Pharmaceutical Physicians, among other professional

societies.

schnipper@cellgate.comThis email address is being protected from spam bots, you need Javascript enabled to view it